Thurtle DR, et al. - Given that prognostic stratification is the cornerstone of management in nonmetastatic prostate cancer (PCa), researchers developed and validated an individualised prognostic model for nonmetastatic PCa. For this investigation, they produced a model that could contextualize the relative PCa - specific and overall survival outcomes for an individual with newly diagnosed disease and allow modelling on these outcomes of the potential benefit of therapy. Investigators found that in both validation sets, the new risk model called ‘PREDICT Prostate’ predicted survival outcomes with a high degree of accuracy with concordance indices up to 0.84. For easy access and utility, they have now integrated the model into a web-based interface. Despite the use of only routinely collected clinicopathological information, prognostic power is high.